Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT)‘s stock had its “outperform” rating reaffirmed by equities research analysts at Wedbush in a research report issued to clients and investors on Friday, May 26th. They presently have a $231.00 price target on the biopharmaceutical company’s stock. Wedbush’s target price indicates a potential upside of 95.10% from the company’s previous close.
A number of other analysts also recently weighed in on ICPT. Oppenheimer Holdings, Inc. set a $200.00 price target on Intercept Pharmaceuticals and gave the company a “buy” rating in a research note on Saturday, February 11th. FBR & Co reissued a “market perform” rating and issued a $200.00 price target on shares of Intercept Pharmaceuticals in a report on Thursday, February 16th. Needham & Company LLC reiterated a “hold” rating on shares of Intercept Pharmaceuticals in a research note on Thursday, February 23rd. Robert W. Baird reissued an “outperform” rating and set a $332.00 price target on shares of Intercept Pharmaceuticals in a research report on Thursday, February 16th. Finally, BMO Capital Markets reissued an “outperform” rating and set a $198.00 price target on shares of Intercept Pharmaceuticals in a research report on Thursday, February 16th. Three equities research analysts have rated the stock with a sell rating, five have assigned a hold rating, nine have assigned a buy rating and one has issued a strong buy rating to the stock. Intercept Pharmaceuticals currently has a consensus rating of “Hold” and a consensus price target of $190.98.
Shares of Intercept Pharmaceuticals (ICPT) traded up 0.24% during mid-day trading on Friday, hitting $118.40. 474,200 shares of the stock were exchanged. The stock’s 50 day moving average is $116.20 and its 200-day moving average is $113.79. The stock’s market cap is $2.96 billion. Intercept Pharmaceuticals has a 12 month low of $96.63 and a 12 month high of $177.93.
Intercept Pharmaceuticals (NASDAQ:ICPT) last announced its earnings results on Thursday, May 4th. The biopharmaceutical company reported ($3.61) earnings per share for the quarter, beating the consensus estimate of ($4.27) by $0.66. Intercept Pharmaceuticals had a negative return on equity of 116.30% and a negative net margin of 825.58%. The company had revenue of $21 million for the quarter, compared to the consensus estimate of $15.88 million. During the same period last year, the business posted ($5.17) EPS. The company’s revenue was up 4566.7% on a year-over-year basis. On average, analysts anticipate that Intercept Pharmaceuticals will post ($14.50) EPS for the current year.
COPYRIGHT VIOLATION WARNING: This article was first published by Sports Perspectives and is owned by of Sports Perspectives. If you are reading this article on another publication, it was copied illegally and reposted in violation of US & international copyright & trademark laws. The legal version of this article can be viewed at https://sportsperspectives.com/2017/06/17/intercept-pharmaceuticals-inc-icpt-rating-reiterated-by-wedbush-updated-updated.html.
In other news, CMO David Shapiro sold 346 shares of the company’s stock in a transaction dated Monday, April 3rd. The shares were sold at an average price of $115.00, for a total value of $39,790.00. Following the sale, the chief marketing officer now directly owns 46,023 shares of the company’s stock, valued at approximately $5,292,645. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, insider Lisa Bright sold 698 shares of the stock in a transaction dated Thursday, June 1st. The shares were sold at an average price of $110.73, for a total transaction of $77,289.54. Following the completion of the transaction, the insider now directly owns 24,711 shares in the company, valued at $2,736,249.03. The disclosure for this sale can be found here. Insiders have sold a total of 4,016 shares of company stock valued at $452,624 in the last ninety days. Company insiders own 9.20% of the company’s stock.
Several hedge funds have recently bought and sold shares of the company. FMR LLC raised its stake in Intercept Pharmaceuticals by 0.3% in the fourth quarter. FMR LLC now owns 3,721,316 shares of the biopharmaceutical company’s stock valued at $404,321,000 after buying an additional 12,360 shares in the last quarter. Vanguard Group Inc. increased its position in shares of Intercept Pharmaceuticals by 4.7% in the first quarter. Vanguard Group Inc. now owns 1,270,984 shares of the biopharmaceutical company’s stock valued at $143,749,000 after buying an additional 56,952 shares during the last quarter. State Street Corp increased its position in shares of Intercept Pharmaceuticals by 7.3% in the first quarter. State Street Corp now owns 805,550 shares of the biopharmaceutical company’s stock valued at $91,110,000 after buying an additional 54,523 shares during the last quarter. Macquarie Group Ltd. increased its position in shares of Intercept Pharmaceuticals by 54.2% in the first quarter. Macquarie Group Ltd. now owns 241,565 shares of the biopharmaceutical company’s stock valued at $27,321,000 after buying an additional 84,954 shares during the last quarter. Finally, Point72 Asset Management L.P. increased its position in shares of Intercept Pharmaceuticals by 13.1% in the first quarter. Point72 Asset Management L.P. now owns 220,600 shares of the biopharmaceutical company’s stock valued at $24,950,000 after buying an additional 25,500 shares during the last quarter. Institutional investors and hedge funds own 84.39% of the company’s stock.
About Intercept Pharmaceuticals
Intercept Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics to treat non-viral, progressive liver diseases. The Company’s product candidates have the potential to treat orphan and more prevalent diseases for which there are limited therapeutic solutions.
Receive News & Ratings for Intercept Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intercept Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.